Sensitive Detection of Cell-Free Tumour DNA Using Optimised Targeted Sequencing Can Predict Prognosis in Gastro-Oesophageal Cancer.

cancer cell-free (tumour) DNA gastric liquid biopsy oesophageal prognostic biomarker

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
11 Feb 2023
Historique:
received: 29 11 2022
revised: 03 02 2023
accepted: 09 02 2023
entrez: 25 2 2023
pubmed: 26 2 2023
medline: 26 2 2023
Statut: epublish

Résumé

In this longitudinal study, cell-free tumour DNA (a liquid biopsy) from plasma was explored as a prognostic biomarker for gastro-oesophageal cancer. Both tumour-informed and tumour-agnostic approaches for plasma variant filtering were evaluated in 47 participants. This was possible through sequencing of DNA from tissue biopsies from all participants and cell-free DNA from plasma sampled before and after surgery (n = 42), as well as DNA from white blood cells (n = 21) using a custom gene panel with and without unique molecular identifiers (UMIs). A subset of the plasma samples (n = 12) was also assayed with targeted droplet digital PCR (ddPCR). In 17/31 (55%) diagnostic plasma samples, tissue-verified cancer-associated variants could be detected by the gene panel. In the tumour-agnostic approach, 26 participants (59%) had cancer-associated variants, and UMIs were necessary to filter the true variants from the technical artefacts. Additionally, clonal haematopoietic variants could be excluded using the matched white blood cells or follow-up plasma samples. ddPCR detected its targets in 10/12 (83%) and provided an ultra-sensitive method for follow-up. Detectable cancer-associated variants in plasma correlated to a shorter overall survival and shorter time to progression, with a significant correlation for the tumour-informed approaches. In summary, liquid biopsy gene panel sequencing using a tumour-agnostic approach can be applied to all patients regardless of the presence of a tissue biopsy, although this requires UMIs and the exclusion of clonal haematopoietic variants. However, if sequencing data from tumour biopsies are available, a tumour-informed approach improves the value of cell-free tumour DNA as a negative prognostic biomarker in gastro-oesophageal cancer patients.

Identifiants

pubmed: 36831507
pii: cancers15041160
doi: 10.3390/cancers15041160
pmc: PMC9954085
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Region Stockholm
ID : K2891-2016
Organisme : Region Stockholm
ID : FoUI-961732, SLL-500306, and SLL-581046
Organisme : The Swedish Childhood Cancer Fund Barncancerfonden
ID : KP2021-0017, KP0009, TJ2021-0125 and TJ0054

Déclaration de conflit d'intérêts

V.W. received speaker’s honoraria from Illumina and Roche, apart from that the authors declare no conflict of interest.

Références

Gastric Cancer. 2022 Mar;25(2):401-410
pubmed: 34714423
Nucleic Acids Res. 2019 Jan 8;47(D1):D941-D947
pubmed: 30371878
Gastroenterology. 2020 Feb;158(3):494-505.e6
pubmed: 31711920
Cancer Sci. 2022 May;113(5):1830-1842
pubmed: 35293110
Nature. 2020 May;581(7809):434-443
pubmed: 32461654
Nat Rev Genet. 2018 May;19(5):269-285
pubmed: 29576615
Clin Transl Gastroenterol. 2021 Sep 24;12(9):e00403
pubmed: 34644276
Sci Rep. 2021 Nov 11;11(1):22103
pubmed: 34764347
PLoS One. 2021 Feb 4;16(2):e0245488
pubmed: 33539436
Nature. 2020 Apr;580(7802):245-251
pubmed: 32269342
Nat Biotechnol. 2016 May;34(5):547-555
pubmed: 27018799
Nucleic Acids Res. 2018 Jan 4;46(D1):D1062-D1067
pubmed: 29165669
Cancer Manag Res. 2021 Mar 05;13:2223-2234
pubmed: 33707971
Proc Natl Acad Sci U S A. 2020 Mar 3;117(9):4858-4863
pubmed: 32075918
Genome Biol. 2016 Jun 06;17(1):122
pubmed: 27268795
Nat Commun. 2020 Jan 27;11(1):525
pubmed: 31988276
Cancers (Basel). 2020 Aug 14;12(8):
pubmed: 32823942
Bioinformatics. 2018 Sep 1;34(17):i884-i890
pubmed: 30423086
JAMA Oncol. 2018 Nov 1;4(11):1589-1593
pubmed: 29872864
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
Mol Oncol. 2020 Aug;14(8):1670-1679
pubmed: 32471011
Bioinformatics. 2016 Oct 1;32(19):3047-8
pubmed: 27312411
Sci Transl Med. 2014 Feb 19;6(224):224ra24
pubmed: 24553385
Br J Cancer. 2020 Oct;123(8):1271-1279
pubmed: 32719550
Prenat Diagn. 2015 Aug;35(8):810-5
pubmed: 25967380
Nucleic Acids Res. 2016 Jun 20;44(11):e108
pubmed: 27060149
Cell Death Dis. 2020 May 11;11(5):346
pubmed: 32393783

Auteurs

Karin Wallander (K)

Department of Molecular Medicine and Surgery, Karolinska Institutet, 17176 Stockholm, Sweden.
Department of Clinical Genetics, Karolinska University Hospital, 17164 Stockholm, Sweden.

Zahra Haider (Z)

Department of Molecular Medicine and Surgery, Karolinska Institutet, 17176 Stockholm, Sweden.

Ashwini Jeggari (A)

Science for Life Laboratory, Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, 17165 Stockholm, Sweden.

Hassan Foroughi-Asl (H)

Department of Molecular Medicine and Surgery, Karolinska Institutet, 17176 Stockholm, Sweden.

Anna Gellerbring (A)

Science for Life Laboratory, Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, 17165 Stockholm, Sweden.

Anna Lyander (A)

Science for Life Laboratory, Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, 17165 Stockholm, Sweden.
Science for Life Laboratory, School of Chemistry, Biotechnology and Health, Royal Institute of Technology, 10044 Stockholm, Sweden.

Athithyan Chozhan (A)

Department of Molecular Medicine and Surgery, Karolinska Institutet, 17176 Stockholm, Sweden.

Ollanta Cuba Gyllensten (O)

Department of Molecular Medicine and Surgery, Karolinska Institutet, 17176 Stockholm, Sweden.

Moa Hägglund (M)

Science for Life Laboratory, Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, 17165 Stockholm, Sweden.

Valtteri Wirta (V)

Science for Life Laboratory, Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, 17165 Stockholm, Sweden.
Science for Life Laboratory, School of Chemistry, Biotechnology and Health, Royal Institute of Technology, 10044 Stockholm, Sweden.
Genomic Medicine Center Karolinska, Karolinska University Hospital, 17164 Stockholm, Sweden.

Magnus Nordenskjöld (M)

Department of Molecular Medicine and Surgery, Karolinska Institutet, 17176 Stockholm, Sweden.

Mats Lindblad (M)

Department of Clinical Science, Intervention and Technology, Karolinska Institutet, 14152 Huddinge, Sweden.
Department of Upper Abdominal Diseases, Karolinska University Hospital, 17164 Stockholm, Sweden.

Emma Tham (E)

Department of Molecular Medicine and Surgery, Karolinska Institutet, 17176 Stockholm, Sweden.
Department of Clinical Genetics, Karolinska University Hospital, 17164 Stockholm, Sweden.

Classifications MeSH